Radioimmunotherapy and Temozolomide in the Treatment of Glioblastoma Multiforme: A 20 Year Experience

Li, L.; Quang, Tony S.; Gracely, Ed; Emrich, Jacqueline; Kim, J.; Yaeger, Theodore E.; Jenrette, Joseph M.; Cohen, Steven C.; Brady, Luther W.

doi:10.1016/j.ijrobp.2007.07.088

Cited by 1 publication

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two phase I trials with the EGFR-specific mAb nimotuzumab labeled with 188-Re have been published [18,101] and a median overall survival of 18.7 months was reported. The use of EGFR (and variants) as a target is restricted by the fact that only 60-80% of high-grade gliomas [56], according to other studies only 50-60% [34,65] of gliomas, overexpress the molecule.…”

Section: Other Targetsmentioning

confidence: 99%

“…However, two trials compared RIT alone with RIT plus adjuvant temozolomide (TMZ): Bartolomei et al [7] The median overall survival in the first group was 17.5 months and was significantly prolonged to 25 months in the iRIT + TMZ group. Li et al [56], in a long-term phase II observational study, used systemically applied I-125-labeled anti-EGFR mAb 425 (3 cycles of 50 mCi, totaling 150 mCi), starting 4-6 weeks after completion of surgery and radiotherapy. Among the 192 patients, 132 were treated with I-125-mAb 425 alone and 60 at a later time were treated with I-125-mAb 425 plus temozolomide.…”

Section: Other Targetsmentioning

confidence: 99%

“…With the availability of new mAbs [14,18,26,56,101] or smaller compounds such as peptides and engineered antibody fragments [26,40] on the one side, and improved radiochemistry on the other, there is revived interest in this promising…”

Section: New Experimental Developments In Iritmentioning

confidence: 99%

“…In a few trials, radioimmunoconjugates (RICs) were delivered by intravenous injection. Li et al [56], in the above-mentioned study (see BOther targets^section), compared 132 patients treated with I-125-mAb 425 alone with 60 patients treated with I-125-I-mAb plus temozolomide. The median survival was 14.5 months (12.1-16.7) in the RIT group and 20.4 months (14.9-25.8) in the RIT plus TMZ group.…”

Section: Systemic Deliverymentioning

confidence: 99%

“…The median survival was 14.5 months (12.1-16.7) in the RIT group and 20.4 months (14.9-25.8) in the RIT plus TMZ group. The authors themselves mention that during the long span, over 20 years, many treatment changes and advancements have taken place [15,56]. Wygoda et al [106] compared radiotherapy alone (10 patients) versus radiotherapy plus intravenous (eight patients) administration of anti-EGFR-I-125-mAb 425) in patients with grades III and IV glioma.…”

Section: Systemic Deliverymentioning

confidence: 99%

See 4 more Smart Citations

Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments

et al. 2019

View full text Add to dashboard Cite

There is a distinct need for new and second-line therapies to delay or prevent local tumor regrowth after current standard of care therapy. Intracavitary radioimmunotherapy, in combination with radiotherapy, is discussed in the present review as a therapeutic strategy of high potential. We performed a systematic literature search following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). The available body of literature on intracavitary radioimmunotherapy (iRIT) in glioblastoma and anaplastic astrocytomas is presented. Several past and current phase I and II clinical trials, using mostly an antitenascin monoclonal antibody labeled with I-131, have shown median overall survival of 19-25 months in glioblastoma, while adverse events remain low. Tenascin, followed by EGFR and variants, or smaller peptides have been used as targets, and most clinical studies were performed with I-131 or Y-90 as radionuclides while only recently Re-188, I-125, and Bi-213 were applied. The pharmacokinetics of iRIT, as well as the challenges encountered with this therapy, is comprehensively discussed. This promising approach deserves further exploration in future studies by incorporating several innovative modifications.

show abstract